Faculty

Rutika Mehta

MD, MPH
Associate Professor, Division of Hematology/Oncology
Weill Cornell Medicine/New York Presbyterian Hospital

Rutika Mehta MD, MPH is an Associate Professor in Medicine and Attending Physician at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Dr. Mehta received her medical degree at Topiwala National Medical College in Mumbai, India. She subsequently completed a Masters in Public Health with a focus on Epidemiology at Indiana University, Indianapolis. She spent three years as a Research Fellow in the Department of Pathology at Indiana University School of Medicine. She then completed her training in Internal Medicine at Johns Hopkins University/Sinai Hospital of Baltimore followed by a fellowship in Hematology/Oncology at Roswell Park Comprehensive Cancer Institute in Buffalo, New York. After completing her hematology and oncology training, Dr. Mehta joined the gastrointestinal (GI) oncology department at the H. Lee Moffitt Cancer Center in Tampa, Florida. At Moffit Cancer Center, Dr. Mehta worked with many renowned leaders in the field and was instrumental in building the clinical and research program for upper GI malignancies. She was selected as a Castle Connolly “Top Doctor” for three straight years in the Tampa Bay area (2022-2024). She is an active member of the American Society of Clinical Oncology (ASCO) and serves as a member of the National Cancer Institute (NCI) Taskforce for Esophagogastric Cancers. Dr. Mehta was recruited to Weill Cornell Medicine (WCM) in 2024. Her clinical and research efforts will focus on all GI cancers with a particular emphasis on developing clinical trials utilizing novel treatment options and advancing the field through precision medicine.

2026 Sessions

General Session

IO Rechallenge in Esophageal and Gastric Cancers: Balancing Safety Concerns vs Potential Benefit of Reinitiation

Explore the role of immunotherapy (IO) rechallenge in the management of esophageal and gastric cancers, weighing safety concerns against the potential clinical benefit of...

  • Moderator
    • Cathy Eng, MD, FACP, FASCO
    • Yelena Janjigian, MD
  • Presenter
    • Tiago Biachi, MD, PhD
    • Rutika Mehta, MD, MPH
Gastrointestinal Cancers

Balancing Safety Concerns

Explore the role of immunotherapy (IO) rechallenge in the management of esophageal and gastric cancers, weighing safety concerns against the potential clinical benefit of reinitiation. Speakers will review evidence on efficacy, patterns of response, and the risk of recurrent or cumulative immune-related adverse events, and address clinical scenarios in which IO rechallenge may be appropriate.

This session will focus on safety considerations surrounding IO rechallenge, covering the incidence and management of recurrent or cumulative immune-related adverse events associated with reinitiation of IO therapy. The discussion will address risk factors, monitoring strategies, and clinical scenarios where rechallenge may pose significant concern, giving participants insight into balancing patient safety with potential therapeutic benefit when considering IO rechallenge.

Presenter

Sunday, March 15 10:25–10:45 AM
Room Royal Ballroom 2
Gastrointestinal Cancers
Faculty

Tiago Biachi

MD, PhD
Associate Professor
Moffitt Cancer Center

Dr. Tiago Biachi de Castria is an Associate Member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center. Dr. Biachi de Castria received his MD degree from Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil. He also obtained a Doctorate degree in Internal Medicine and Therapeutics from São Paulo Federal University. He completed his Residency in Internal Medicine at São Paulo Federal University and his Clinical Oncology Fellowship at the São Paulo University - São Paulo Cancer Institute. Dr. Biachi de Castria was an attending in the Gastrointestinal Oncology Service at the São Paulo Cancer Institute and Sírio-Libanês Hospital. In 2021, he obtained the title of Associate Professor in Gastroenterology Service (São Paulo University) and Associate Professor in Postgraduate Course in Medical Oncology (São Paulo University). Dr. Biachi de Castria most completed a one-year Advanced Fellowship in Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center before joining Moffitt Cancer Center. Dr. Tiago Biachi de Castria’s clinical and research interest is in gastrointestinal malignancies, including biomarkers and drug development.

Potential Benefit of Reinitiation

Explore the role of immunotherapy (IO) rechallenge in the management of esophageal and gastric cancers, weighing safety concerns against the potential clinical benefit of reinitiation. Speakers will review evidence on efficacy, patterns of response, and the risk of recurrent or cumulative immune-related adverse events, and address clinical scenarios in which IO rechallenge may be appropriate.

Faculty will review emerging clinical evidence and real-world data suggesting renewed antitumor activity in select patients following reinitiation of IO therapy. Discussion will address factors associated with response, optimal timing, and patient selection. Participants will gain perspective on scenarios in which IO rechallenge may offer meaningful clinical benefit despite prior treatment exposure.

Presenter

Sunday, March 15 10:45–11:05 AM
Room Royal Ballroom 2
Gastrointestinal Cancers
Faculty

Rutika Mehta

MD, MPH
Associate Professor, Division of Hematology/Oncology
Weill Cornell Medicine/New York Presbyterian Hospital

Rutika Mehta MD, MPH is an Associate Professor in Medicine and Attending Physician at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Dr. Mehta received her medical degree at Topiwala National Medical College in Mumbai, India. She subsequently completed a Masters in Public Health with a focus on Epidemiology at Indiana University, Indianapolis. She spent three years as a Research Fellow in the Department of Pathology at Indiana University School of Medicine. She then completed her training in Internal Medicine at Johns Hopkins University/Sinai Hospital of Baltimore followed by a fellowship in Hematology/Oncology at Roswell Park Comprehensive Cancer Institute in Buffalo, New York. After completing her hematology and oncology training, Dr. Mehta joined the gastrointestinal (GI) oncology department at the H. Lee Moffitt Cancer Center in Tampa, Florida. At Moffit Cancer Center, Dr. Mehta worked with many renowned leaders in the field and was instrumental in building the clinical and research program for upper GI malignancies. She was selected as a Castle Connolly “Top Doctor” for three straight years in the Tampa Bay area (2022-2024). She is an active member of the American Society of Clinical Oncology (ASCO) and serves as a member of the National Cancer Institute (NCI) Taskforce for Esophagogastric Cancers. Dr. Mehta was recruited to Weill Cornell Medicine (WCM) in 2024. Her clinical and research efforts will focus on all GI cancers with a particular emphasis on developing clinical trials utilizing novel treatment options and advancing the field through precision medicine.

Potential Benefit of Reinitiation

Explore the role of immunotherapy (IO) rechallenge in the management of esophageal and gastric cancers, weighing safety concerns against the potential clinical benefit of reinitiation. Speakers will review evidence on efficacy, patterns of response, and the risk of recurrent or cumulative immune-related adverse events, and address clinical scenarios in which IO rechallenge may be appropriate.

Faculty will review emerging clinical evidence and real-world data suggesting renewed antitumor activity in select patients following reinitiation of IO therapy. Discussion will address factors associated with response, optimal timing, and patient selection. Participants will gain perspective on scenarios in which IO rechallenge may offer meaningful clinical benefit despite prior treatment exposure.

Presenter

Sunday, March 15 10:45–11:05 AM
Room Royal Ballroom 2
Gastrointestinal Cancers
Faculty

Rutika Mehta

MD, MPH
Associate Professor, Division of Hematology/Oncology
Weill Cornell Medicine/New York Presbyterian Hospital

Rutika Mehta MD, MPH is an Associate Professor in Medicine and Attending Physician at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Dr. Mehta received her medical degree at Topiwala National Medical College in Mumbai, India. She subsequently completed a Masters in Public Health with a focus on Epidemiology at Indiana University, Indianapolis. She spent three years as a Research Fellow in the Department of Pathology at Indiana University School of Medicine. She then completed her training in Internal Medicine at Johns Hopkins University/Sinai Hospital of Baltimore followed by a fellowship in Hematology/Oncology at Roswell Park Comprehensive Cancer Institute in Buffalo, New York. After completing her hematology and oncology training, Dr. Mehta joined the gastrointestinal (GI) oncology department at the H. Lee Moffitt Cancer Center in Tampa, Florida. At Moffit Cancer Center, Dr. Mehta worked with many renowned leaders in the field and was instrumental in building the clinical and research program for upper GI malignancies. She was selected as a Castle Connolly “Top Doctor” for three straight years in the Tampa Bay area (2022-2024). She is an active member of the American Society of Clinical Oncology (ASCO) and serves as a member of the National Cancer Institute (NCI) Taskforce for Esophagogastric Cancers. Dr. Mehta was recruited to Weill Cornell Medicine (WCM) in 2024. Her clinical and research efforts will focus on all GI cancers with a particular emphasis on developing clinical trials utilizing novel treatment options and advancing the field through precision medicine.

Case-Based Treatment Strategies in Gastrointestinal Cancers

Moderator

Panelist

Sunday, March 15 11:10–11:55 AM
Room Royal Ballroom 2
Gastrointestinal Cancers
Co-Chair

Cathy Eng

MD, FACP, FASCO
David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program
Vanderbilt-Ingram Cancer Center

Cathy Eng, MD, FACP, FASCO, Professor of Medicine, Hematology and Oncology, is the David H. Johnson Endowed Chair of Surgical and Medical Oncology, VICC Associate Director of Strategic Relations and Research Partnerships, Executive Director of the Young Adults Cancers Program. She was the Ambassador for the American Cancer Society ResearcHERS campaign (2020-2022). She is a highly sought mentor and served on the Vanderbilt-Ingram Mentorship Council and is currently a mentor on the T-32 grant and serves on the Professional Development Mentor. She continues to assume leadership positions devoted to development of phase I-III clinical trials using novel therapeutics for biomarker discovery and enhanced drug utilization in colorectal, appendiceal and anal cancer patients.

Nationally, Dr. Eng has also been highly active serving on multiple committees for ASCO, ECOG, and SWOG. She was chosen for the ASCO Leadership Development Program, ASCO Social Media Committee, the ASCO Colorectal Guidelines Committee, ASCO Scientific Program Committee (Colorectal Cancer Track) and the ASCO Communications Committee. She has served as the co-chair of the SWOG Rectal/Anal Cancer Subcommittee; the Vice-Chair for the SWOG GI Committee; the Chairman of the NCI Rectal/Anal Task Force, member of the NCI GI Steering Committee, and is now the co-Chair of the NCI GI Steering Committee. She participated in the President Biden’s Cancer Moonshot White House Colorectal Cancer Forum.

She has published in many peer-reviewed journals and served on many national grant review panels.

Co-Chair

Yelena Janjigian

MD
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center

Yelena Y. Janjigian, MD is a Professor and Chief of the Gastrointestinal Oncology Service, Carroll and Milton Petrie Chair at Memorial Sloan Kettering Cancer Center (MSK). A physician-scientist, leading translational research and clinical innovation to improve outcomes for patients with GI cancers.

Dr. Janjigian earned her BS from UC San Diego and MD from NYU School of Medicine, completing her residency at NYU/Bellevue and fellowship at MSK. Her research focuses on the molecular characterization of gastroesophageal cancers, driving therapeutic development and brining new drugs to the clinic. She has published over 140 papers in The New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, Lancet, and Nature, with more than 33,000 citations and an H-index of 61.

An elected member of the American Society for Clinical Investigation (ASCI), and Fellows of the American Society of Clinical Oncology (FASCO). Dr. Janjigian serves on the Board of Giants of Cancer Care, Debbie’s Dream Foundation and holds leadership roles in ASCO and AACR. She is also the Scientific Chair for ESMO 2026. Her research, funded by NIH, DOD and SU2C, has shaped new treatment standards in GI oncology.
Beyond research, she is a dedicated mentor, driving innovation and training the next generation of oncology leaders.

Faculty

Tiago Biachi

MD, PhD
Associate Professor
Moffitt Cancer Center

Dr. Tiago Biachi de Castria is an Associate Member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center. Dr. Biachi de Castria received his MD degree from Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil. He also obtained a Doctorate degree in Internal Medicine and Therapeutics from São Paulo Federal University. He completed his Residency in Internal Medicine at São Paulo Federal University and his Clinical Oncology Fellowship at the São Paulo University - São Paulo Cancer Institute. Dr. Biachi de Castria was an attending in the Gastrointestinal Oncology Service at the São Paulo Cancer Institute and Sírio-Libanês Hospital. In 2021, he obtained the title of Associate Professor in Gastroenterology Service (São Paulo University) and Associate Professor in Postgraduate Course in Medical Oncology (São Paulo University). Dr. Biachi de Castria most completed a one-year Advanced Fellowship in Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center before joining Moffitt Cancer Center. Dr. Tiago Biachi de Castria’s clinical and research interest is in gastrointestinal malignancies, including biomarkers and drug development.

Faculty

Rutika Mehta

MD, MPH
Associate Professor, Division of Hematology/Oncology
Weill Cornell Medicine/New York Presbyterian Hospital

Rutika Mehta MD, MPH is an Associate Professor in Medicine and Attending Physician at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Dr. Mehta received her medical degree at Topiwala National Medical College in Mumbai, India. She subsequently completed a Masters in Public Health with a focus on Epidemiology at Indiana University, Indianapolis. She spent three years as a Research Fellow in the Department of Pathology at Indiana University School of Medicine. She then completed her training in Internal Medicine at Johns Hopkins University/Sinai Hospital of Baltimore followed by a fellowship in Hematology/Oncology at Roswell Park Comprehensive Cancer Institute in Buffalo, New York. After completing her hematology and oncology training, Dr. Mehta joined the gastrointestinal (GI) oncology department at the H. Lee Moffitt Cancer Center in Tampa, Florida. At Moffit Cancer Center, Dr. Mehta worked with many renowned leaders in the field and was instrumental in building the clinical and research program for upper GI malignancies. She was selected as a Castle Connolly “Top Doctor” for three straight years in the Tampa Bay area (2022-2024). She is an active member of the American Society of Clinical Oncology (ASCO) and serves as a member of the National Cancer Institute (NCI) Taskforce for Esophagogastric Cancers. Dr. Mehta was recruited to Weill Cornell Medicine (WCM) in 2024. Her clinical and research efforts will focus on all GI cancers with a particular emphasis on developing clinical trials utilizing novel treatment options and advancing the field through precision medicine.

General Session

IO Rechallenge in Esophageal and Gastric Cancers: Balancing Safety Concerns vs Potential Benefit of Reinitiation

Explore the role of immunotherapy (IO) rechallenge in the management of esophageal and gastric cancers, weighing safety concerns against the potential clinical benefit of...

  • Moderator
    • Cathy Eng, MD, FACP, FASCO
    • Yelena Janjigian, MD
  • Presenter
    • Samuel Cytryn, MD
    • Rutika Mehta, MD, MPH
Gastrointestinal Cancers

Balancing Safety Concerns

Explore the role of immunotherapy (IO) rechallenge in the management of esophageal and gastric cancers, weighing safety concerns against the potential clinical benefit of reinitiation. Speakers will review evidence on efficacy, patterns of response, and the risk of recurrent or cumulative immune-related adverse events, and address clinical scenarios in which IO rechallenge may be appropriate.

This session will focus on safety considerations surrounding IO rechallenge, covering the incidence and management of recurrent or cumulative immune-related adverse events associated with reinitiation of IO therapy. The discussion will address risk factors, monitoring strategies, and clinical scenarios where rechallenge may pose significant concern, giving participants insight into balancing patient safety with potential therapeutic benefit when considering IO rechallenge.

Debate Speaker

Sunday, September 27 10:05–10:25 AM
Gastrointestinal Cancers
Faculty

Samuel Cytryn

MD
Assistant Attending, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center

Dr. Samuel Cytryn is an Assistant Attending in the Gastrointestinal Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center. His clinical and research interests involve the use of immune checkpoint blockade and targeted therapy in esophageal and gastric cancers. He is currently the lead on several studies investigating strategies to overcome mechanisms of resistance and immune evasion. He graduated from medical school at the Icahn School of Medicine at Mount Sinai, completed his internal medicine training at New York University, where he served as Chief Resident, and completed his medical oncology training at Memorial Sloan Kettering Cancer Center, where he served as Chief Fellow.

Potential Benefit of Reinitiation

Explore the role of immunotherapy (IO) rechallenge in the management of esophageal and gastric cancers, weighing safety concerns against the potential clinical benefit of reinitiation. Speakers will review evidence on efficacy, patterns of response, and the risk of recurrent or cumulative immune-related adverse events, and address clinical scenarios in which IO rechallenge may be appropriate.

Faculty will review emerging clinical evidence and real-world data suggesting renewed antitumor activity in select patients following reinitiation of IO therapy. Discussion will address factors associated with response, optimal timing, and patient selection. Participants will gain perspective on scenarios in which IO rechallenge may offer meaningful clinical benefit despite prior treatment exposure.

Debate Speaker

Sunday, September 27 10:25–10:45 AM
Gastrointestinal Cancers
Faculty

Rutika Mehta

MD, MPH
Associate Professor, Division of Hematology/Oncology
Weill Cornell Medicine/New York Presbyterian Hospital

Rutika Mehta MD, MPH is an Associate Professor in Medicine and Attending Physician at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Dr. Mehta received her medical degree at Topiwala National Medical College in Mumbai, India. She subsequently completed a Masters in Public Health with a focus on Epidemiology at Indiana University, Indianapolis. She spent three years as a Research Fellow in the Department of Pathology at Indiana University School of Medicine. She then completed her training in Internal Medicine at Johns Hopkins University/Sinai Hospital of Baltimore followed by a fellowship in Hematology/Oncology at Roswell Park Comprehensive Cancer Institute in Buffalo, New York. After completing her hematology and oncology training, Dr. Mehta joined the gastrointestinal (GI) oncology department at the H. Lee Moffitt Cancer Center in Tampa, Florida. At Moffit Cancer Center, Dr. Mehta worked with many renowned leaders in the field and was instrumental in building the clinical and research program for upper GI malignancies. She was selected as a Castle Connolly “Top Doctor” for three straight years in the Tampa Bay area (2022-2024). She is an active member of the American Society of Clinical Oncology (ASCO) and serves as a member of the National Cancer Institute (NCI) Taskforce for Esophagogastric Cancers. Dr. Mehta was recruited to Weill Cornell Medicine (WCM) in 2024. Her clinical and research efforts will focus on all GI cancers with a particular emphasis on developing clinical trials utilizing novel treatment options and advancing the field through precision medicine.

Potential Benefit of Reinitiation

Explore the role of immunotherapy (IO) rechallenge in the management of esophageal and gastric cancers, weighing safety concerns against the potential clinical benefit of reinitiation. Speakers will review evidence on efficacy, patterns of response, and the risk of recurrent or cumulative immune-related adverse events, and address clinical scenarios in which IO rechallenge may be appropriate.

Faculty will review emerging clinical evidence and real-world data suggesting renewed antitumor activity in select patients following reinitiation of IO therapy. Discussion will address factors associated with response, optimal timing, and patient selection. Participants will gain perspective on scenarios in which IO rechallenge may offer meaningful clinical benefit despite prior treatment exposure.

Debate Speaker

Sunday, September 27 10:25–10:45 AM
Gastrointestinal Cancers
Faculty

Rutika Mehta

MD, MPH
Associate Professor, Division of Hematology/Oncology
Weill Cornell Medicine/New York Presbyterian Hospital

Rutika Mehta MD, MPH is an Associate Professor in Medicine and Attending Physician at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Dr. Mehta received her medical degree at Topiwala National Medical College in Mumbai, India. She subsequently completed a Masters in Public Health with a focus on Epidemiology at Indiana University, Indianapolis. She spent three years as a Research Fellow in the Department of Pathology at Indiana University School of Medicine. She then completed her training in Internal Medicine at Johns Hopkins University/Sinai Hospital of Baltimore followed by a fellowship in Hematology/Oncology at Roswell Park Comprehensive Cancer Institute in Buffalo, New York. After completing her hematology and oncology training, Dr. Mehta joined the gastrointestinal (GI) oncology department at the H. Lee Moffitt Cancer Center in Tampa, Florida. At Moffit Cancer Center, Dr. Mehta worked with many renowned leaders in the field and was instrumental in building the clinical and research program for upper GI malignancies. She was selected as a Castle Connolly “Top Doctor” for three straight years in the Tampa Bay area (2022-2024). She is an active member of the American Society of Clinical Oncology (ASCO) and serves as a member of the National Cancer Institute (NCI) Taskforce for Esophagogastric Cancers. Dr. Mehta was recruited to Weill Cornell Medicine (WCM) in 2024. Her clinical and research efforts will focus on all GI cancers with a particular emphasis on developing clinical trials utilizing novel treatment options and advancing the field through precision medicine.

Back to top